HSR22-171: Health-Related Quality of Life, Symptoms, and Tolerability of Loncastuximab Tesirine in Older Versus Younger Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated in a Phase 2 Clinical Trial (LOTIS-2)

Authors:
Alexander Spira Virginia Cancer Specialists Research Institute, Fairfax, VA

Search for other papers by Alexander Spira in
Current site
Google Scholar
PubMed
Close
 MD
,
Laura Liao ADC Therapeutics America Inc., Murray Hill, NJ

Search for other papers by Laura Liao in
Current site
Google Scholar
PubMed
Close
 MS
,
Xiaolei Zhou RTI Health Solutions, Research Triangle Park, NC

Search for other papers by Xiaolei Zhou in
Current site
Google Scholar
PubMed
Close
 PhD
,
Bintu Sherif RTI Health Solutions, Research Triangle Park, NC

Search for other papers by Bintu Sherif in
Current site
Google Scholar
PubMed
Close
 MS
,
Lei Chen ADC Therapeutics America Inc., Murray Hill, NJ

Search for other papers by Lei Chen in
Current site
Google Scholar
PubMed
Close
 PhD
,
David Ungar ADC Therapeutics America Inc., Murray Hill, NJ

Search for other papers by David Ungar in
Current site
Google Scholar
PubMed
Close
 MD
,
Eric Yu ADC Therapeutics America Inc., Murray Hill, NJ

Search for other papers by Eric Yu in
Current site
Google Scholar
PubMed
Close
 PhD
,
John Radford University of Manchester and The Christie NHS Foundation Trust, Manchester Academic Health Centre, Manchester, UK

Search for other papers by John Radford in
Current site
Google Scholar
PubMed
Close
 MD
, and
Mehdi Hamadani Medical College of Wisconsin, Milwaukee, WI

Search for other papers by Mehdi Hamadani in
Current site
Google Scholar
PubMed
Close
 MD

Background: In a single-arm, open-label, phase 2 study (LOTIS 2, NCT03589469), loncastuximab tesirine (loncastuximab tesirine-lpyl; Lonca) has shown antitumor activity with an acceptable toxicity profile and provides stable or improvement in health-related quality of life (HRQOL) in adult patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) after ≥ 2 prior therapies. This analysis evaluates the impact of Lonca on HRQOL, symptoms, and tolerability stratified by age group. Methods: Patients received Lonca as an intravenous infusion on Day 1 of each 3-week treatment cycle. HRQOL change from baseline scores were summarized for EQ-5D visual analog scale (VAS) and the Functional Assessment of Cancer Treatment-Lymphoma (FACT-Lym) by visit and age group. Symptoms related to non-Hodgkin lymphoma or treatment assessed in the FACT-Lym lymphoma subscale were summarized as well as tolerability reported by patient in item GP5 of FACT-Lym. Analysis was conducted using data collected from study initiation (August 2018) through March 2021. Results: A total of 130 patients with a baseline HRQOL score and at least 1 post-baseline score were included in analysis. The median number of Lonca cycles administered was 4 (range, 1-26) and HRQOL completion rate among patients treated at each cycle was greater than 77% through cycle 13. Of those 130 patients, 57 patients were age < 65 years, 53 patients were 65 to < 75 years, and 20 patients were ≥ 75 years. Change from baseline in EQ-5D VAS and FACT-Lym total was stable or improved over the treatment period across all age groups, including age ≥ 75 years. More patients reported improvement than worsening in symptoms of pain, lumps/swelling, and weight loss compared with baseline for a majority of visits, with greater improvement observed in age group ≥ 75 years. A majority of patients reported “a little bit” or “not at all” when being asked how much was bothered by side effects of treatment and a higher percentage of patients in age group ≥ 75 years reported “not at all” than in younger age groups (e.g., at cycle 4, 24% not at all and 44% a little bit in < 65 years, 42% and 25% in 65 to < 75 years, and 67% and 0% in ≥ 75 years). Conclusions: The overall health state and HRQOL were stable or improved in all age groups of patients treated with Lonca. The older age group (≥ 75 years) reported greater improvement in pain, lumps/swelling, and weight loss and better tolerability to treatment side effect.

F1

Figure. Mean Change from Baseline in EQ-5 D VAS and FACT -Lym Total by Visit and Age Group

Errors bars indicate ± standard error. Visits with less than 5 assessments in total are not displayed. A change of 7 points for VAS or FACT-Lym total is considered minimally important difference.

Citation: Journal of the National Comprehensive Cancer Network 20, 3.5; 10.6004/jnccn.2021.7242

Corresponding Author: Bintu Sherif, MS
  • Collapse
  • Expand
  • View in gallery

    Figure. Mean Change from Baseline in EQ-5 D VAS and FACT -Lym Total by Visit and Age Group

    Errors bars indicate ± standard error. Visits with less than 5 assessments in total are not displayed. A change of 7 points for VAS or FACT-Lym total is considered minimally important difference.

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 306 306 17
PDF Downloads 0 0 0
EPUB Downloads 0 0 0